<DOC>
	<DOCNO>NCT00597519</DOCNO>
	<brief_summary>In study two cord blood collection use increase number cord blood cell receive transplant day . We call `` double unit '' cord blood transplant . A previous study suggest double unit cord blood transplant may better result . The main purpose study find good cord blood transplant use two cord blood collection two different baby cure cancer . Double unit cord blood transplant study way increase number cord blood cell give big child adult patient . Based study already do double unit cord blood transplant appear safer one cord blood unit use . However , double unit cord blood transplant fairly new form treatment .</brief_summary>
	<brief_title>A Myeloablative Conditioning Regimen Total Body Irradiation Followed Transplantation Patients With Hematological Malignancy</brief_title>
	<detailed_description>This single arm phase 2 study obtain preliminary estimate efficacy myeloablative double unit umbilical cord blood transplantation ( UCBT ) measure overall disease-free survival 1 year post transplantation . The UCB graft consist two ( double ) unit two unrelated newborn donor . Patients hematopoietic malignancy high-risk relapse advance disease receive myeloablative conditioning cyclophosphamide ( Cy ) , low dose fludarabine ( Flu ) total body irradiation ( TBI ) post transplantation cyclosporine ( CSA ) mycophenolate mofetil ( MMF ) GVHD prophylaxis .</detailed_description>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Age 4 50 year Patient relate unrelated volunteer donor suitably HLA match available required time period suitable candidate autologous stem cell transplant . Patients one follow hematological malignancy : Acute myelogenous leukemia ( AML ) : Complete first remission ( CR1 ) high risk relapse define : know prior diagnosis myelodysplasia ( MDS ) ; therapy related AML ; White cell count presentation &gt; 100,000 ; Presence extramedullary leukemia diagnosis ; Unfavorable FAB type ( M0 , M57 ) ; Highrisk cytogenetics ( associate MDS , abnormalities 5 , 7 , 8 , Philadelphia chromosome , complex karyotype ) ; High risk molecular marker FLT3 mutation ; Requirement 2 induction achieve CR1 Complete second CR ( CR2 ) . • Acute lymphoblastic leukemia ( ALL ) : Complete first remission ( CR1 ) high risk relapse define : White cell count presentation follow : &gt; 100,000 &lt; 18 year &gt; 50,000 &gt; 18 year ; Presence extensive extramedullary disease ( exclude CNS disease ) ; Presence highrisk cytogenetic abnormality ( 9 ; 22 ) , ( 1 ; 19 ) , ( 4 ; 11 ) MLL rearrangement ( 11q23 ) , ( 8 ; 14 ) [ exclude BALL pediatric patient ] ; Failed achieve complete remission four week induction therapy Unable receive require consolidation chemotherapy would need maintain remission Complete second third remission ( CR2 CR3 ) Acute undifferentiated leukemia ( AUL ) , infant leukemia , biphenotypic leukemia CR1 , CR2 CR3 . Patients infant leukemia must eligible receive total body irradiation . Juvenile Myelomonocytic leukemia ( JMML ) &lt; 30 % bone marrow blast . Chronic myelogenous leukemia ( CML ) GleevecTM failure 1st 2nd chronic phase ; Gleevec failure 1st 2nd accelerated phase . • Myelodysplastic Syndrome ( MDS ) one follow : Low ( Score 0 ) International Prognostic Scoring System ( IPSS ) score Lifethreatening cytopenia ( ) ; Red cell platelet transfusion dependent Intermediate ( Score 1 ) High ( Score 2 ) International Prognostic Scoring System ( IPSS ) score . Patients bone marrow blast &gt; 10 % AML induction therapy disease response &lt; 5 % blast least partial count recovery . • NonHodgkin 's Lymphoma Patients highgrade disease follow initial therapy appropriate chemotherapy autologous stem cell transplantation . Patients highgrade diffuse large cell NHL recurrent disease first remission must : Chemosensitivity evidence &gt; partial remission ( PR ) ( define &gt; 50 % reduction mass size therapy ) . Patients adequate organ function performance status criterion measure : Karnofsky score &gt; = 70 % Lansky score &gt; = 70 % Renal : Calculated creatinine clearance &gt; = 60 ml/min Hepatic : Total bilirubin &lt; 2.5 mg/dL unless benign congenital hyperbilirubinemia ( Gilbert 's syndrome ) ALT/AST &lt; 3 x upper limit normal Albumin &gt; = 2.5 Pulmonary : Pulmonary function ( spirometry correct DLCO ) &gt; = 60 % normal available ( small child use History Physical CT scan necessary determine pulmonary status ) Cardiac : Left ventricular ejection fraction &gt; = 50 % Double Unit Umbilical Cord Blood Grafts : Units select base HLA match patient basis individual combine cell dos unit . Patient related unrelated volunteer donor suitably HLA match available required time period . Patient candidate autologous stem cell transplant . Active CNS leukemia . Acute Myelogenous Leukemia great CR2 . Acute Myelogenous Leukemia evolve myelofibrosis . Acute Lymphoblastic Leukemia , acute undifferentiated leukemia , biphenotypic leukemia infant leukemia great CR3 . Any acute leukemia : Morphologic relapse persistent disease BM ( cytogenetic relapse without morphologic evidence relapse cytogenetic persistent disease BM acceptable ) ; Active extramedullary leukemia ; Requiring great 2 cycle chemotherapy obtain present remission status ; Bone Marrow aplasia ( define BM cellularity le 5 % transplant workup ) ; MDS great 10 % bone marrow blast refractory chemotherapy ; CML blast crisis ; NHL refractory chemotherapy ( less PR 2 regimen ) ; Prior autologous allogeneic HSC transplant time ; Prior radiation therapy render patient ineligible TBI ; Uncontrolled viral , bacteria fungal infection time study enrollment ; Seropositive NAT positive HIV ; Females pregnant breast feeding ; Patient guardian unable give inform consent unable comply treatment protocol include appropriate supportive care , followup , research test .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>Non-Hodgkin 's Lymphoma</keyword>
	<keyword>Total Body Irradiation</keyword>
	<keyword>Umbilical Cord Blood Grafts</keyword>
	<keyword>06-014</keyword>
</DOC>